BRAF V600E mutations may be associated with thyroid cancer progression, have been defined as thyroid oncogenes experimentally, and may be, in part, responsible for tumour dedifferentiation and loss of response to standard therapies, such as TSH suppression and radioiodine. This evidence concerns the gene BRAF and thyroid gland carcinoma.